Into the Aftermath of M&A

September 1, 2009
Kenneth A. Getz

Applied Clinical Trials

Applied Clinical Trials, Applied Clinical Trials-09-01-2009, Volume 0, Issue 0

Mergers and acquisitions volume is way up, but have they fulfilled their intended purpose?

The recent wave of merger and acquisition activity among pharmaceutical and biotechnology companies is strong and likely to continue through 2010. Some of the most notable transactions during 2008 and 2009 to date include Pfizer's acquisition of Wyeth; Merck's agreement to purchase Schering-Plough; Takeda Pharmaceutical's acquisition of Millenium Pharmaceuticals; Eli Lilly's unexpected bid and acquisition of ImClone Systems; and Roche's hostile bid for Genentech.

Kenneth A. Getz

The rationale for M&A transactions seems straightforward enough: Large and mid-size companies typically pursue mergers and acquisitions to build up their pipelines and to strengthen their market positions. Small sponsors have traditionally pursued being acquired in order to secure more capital for R&D investment or as an exit strategy. But in practice, mergers and acquisitions appear to either fall short of expectations or to impact drug development spending and productivity in unintended ways. Speak with anyone who has lived through a merger or acquisition and you'll receive an earful of experiences and anecdotes supporting this statement.

Earlier this year, my Tufts Center colleagues and I conducted a study to quantify the impact of M&A transactions on drug development spending and productivity. We analyzed transactions announced and completed between 1998 and 2004. Our findings shed some light on what happens to drug pipelines and R&D spending post-transaction and offer insight for sponsors, CROs, investigative sites, and financial professionals into forecasting and anticipating the impact of M&As.

Recent transactions

Tufts CSDD analyzed development pipeline and spending data from published sources on 24 of the total 26 major independent transactions among 41 merged and/or acquired companies completed between 1998 and 2004. Major deals were defined as those that exceeded $1 billion in transaction value among publicly-traded independent entities. Two transactions were not included in the analysis because one was acquired by a larger company during our observation period and the other lacked sufficient data to allow for our detailed analysis. Also, organizations that are subsidiaries of diversified holding companies were not included in our analysis.

In order to understand sponsors' development pipelines and spending practices prior to an M&A transaction, my colleagues and I looked at published development data for each of the companies involved nearly two years before the transaction announcement. We then compared that retrospective data with pipeline and spending data two years and four years after each transaction was announced.

Transactions were also organized into subgroups: "Large" versus "Small" acquirers, for which the former group had to include one of the 20 largest pharmaceutical companies by revenue at the time of the merger; and "Mergers" versus "Acquisitions," the latter being defined as transactions implemented by buyers whose annual revenue is more than three times larger than that of the acquired party.

Smaller portfolios

Companies that go through a merger or acquisition consolidated their portfolios, particularly transactions involving smaller companies. Pipeline consolidation was likely due to a number of factors. Following a transaction and during the integration period, companies tend to trim their portfolios to free-up and reallocate resources. Projects deemed noncore and marginal are the first to be cut along with those that lack an internal champion or have not been adequately resourced.

The typical biopharmaceutical company saw a 6.4% annual increase between 1998 and 2004. But companies that went through a merger or acquisition saw a significant 2.9% annual decrease in the number of drugs in their development portfolios from two years prior to four years after the transaction announcement. This decline was most pronounced among merged and acquired companies in Phase III, where the number of drugs dropped nearly 7% each year. For the industry benchmark the number of drugs in Phase III studies saw relatively flat annual growth (0.5%) between 1998 and 2004.

Annual growth rates in the number of drugs in Phase I studies were similar for merged or acquired companies and the industry benchmark. The annual growth rate in the number of drugs in Phase II for merged and acquired companies was considerably slower (3%) compared to the industry benchmark (8.5%).

Small acquirers saw substantially higher contraction (10.1%) in the number of drugs overall in development two years prior to four years after the transaction. This compares with a 1.6% decline in the number of drugs in development overall for large acquirers during that period. Both small and large acquirers consolidated the number of late-stage Phase III drugs in development. In Phase I the annual growth rate in the number of drugs for both small and large acquirers increased more modestly relative to the industry benchmark. Large acquirers saw substantially higher annual growth rates in the number of drugs in Phase II than did small acquirers.

Merged entities consolidated the number of drugs in the pipeline overall and in early Phase I studies. Acquisitions on the other hand saw substantially higher annual growth in Phase I activity compared with merged companies and the industry benchmark. The number of drugs in Phase II development for companies that merged grew at annual rates well above industry benchmarks. Both merged companies and acquisitions consolidated their Phase III programs.

Accelerated R&D spending

Annual growth in R&D spending is substantially higher for companies that have gone through an M&A—particularly smaller acquisitions—compared to that of the industry benchmark. Following the completion of a transaction, the combined organization must confront integration challenges, resource uncertainty, and operational instability.

During integration, drug developers tend to reallocate a higher proportion of their financial resources outside of R&D. As a result, they must rationalize their portfolios in order to adequately invest in priority projects. Companies may also be allocating more resources and time to leverage the value and synergies of the combined entity after the transaction is completed.

Merged and acquired companies increased their overall R&D spending significantly by 14% annually beginning two years before and ending four years after the transaction announcement. Small acquisitions increased R&D spending 19.2% annually—10 percentage points higher than the average annual R&D spending growth rate among large acquisitions. The typical company increased R&D spending annually by 10.8% between 1998 and 2004. Among merged and acquired companies, annual R&D spending growth rose the fastest (23%) during the period two years to four years after the transaction announcement.

Higher failure rates

Compared to industry benchmarks, merged and acquired companies have higher Phase I and Phase III failure rates and higher success rates in Phase II. Merged and acquired companies have trimmed their late stage portfolios and therefore development risk is spread across fewer candidates. Higher attrition rates may also be due to integration uncertainty, particularly personnel turnover associated with M&A transactions and other resource allocation issues.

Among companies completing a merger or acquisition, 46.4% of compounds in Phase I failed compared with the benchmark failure rate of 30.8%; 46.6% of the compounds that made it to Phase II were terminated compared with the benchmark rate of 58.8%; and 29.9% were terminated in Phase III compared with the benchmark rate of 21.5%.

Future expectations

Having completed a merger or acquisition, sponsor companies face substantial integration challenges and uncertainty leading them to consolidate their pipelines while increasing R&D spending at a faster rate each year than industry norms. For service providers—including CROs, investigative sites, central labs, eCT solutions providers—M&A transactions present unprecedented, and increasing, volatility.

Under the current economic environment, large and mid-sized pharmaceutical and biotechnology companies are bullish about finding acquisition bargains. Company valuations are low and many smaller organizations are desperately seeking capital. In turn, larger, better-capitalized organizations see a buyer's market for enriching their pipelines and their R&D talent pool and capabilities. Our recent study begins to quantify the impact of M&A transactions on portfolio and R&D spending growth.

Kenneth A. Getz MBA, is a Senior Research Fellow at the Tufts CSDD and Chairman of CISCRP, both in Boston, MA, email: kenneth.getz@tufts.edu

Related Content:

News